Reforgene named a Top 10 cell and gene therapy company in the 2021 biopharma value rankings
On December 13, 2021, the VB100-2021 Future Healthcare Biopharma Value List was announced. The list includes two major industry directions: cell and gene therapy, and AI-driven new drug R&D. Reforgene was selected into the "Cell & Gene Therapy TOP10". *Enterprises are listed by the first letter of their names. http://vb100.vcbeat.top/
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com · BD@reforgene.com